Day: August 6, 2024

Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on August 6, 2024. Posted in Public Companies.

Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected in fourth quarter of 2024 Progressing clinical studies in MDD, bipolar depression and Alzheimer’s disease agitation, providing opportunity for multiple value-creating catalysts over next 18 months Strong financial position with $371.6 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. “The first half of the year was marked by considerable progress across our robust clinical development...

TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

Written by Customer Service on August 6, 2024. Posted in Public Companies.

Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 – $300 million Cash flow positive for second quarter 2024 Establishes $250 million credit facility to repay existing debt and to buy back up to $100 million of common stock under a share repurchase program Initiated phase 1 study in RMS patients for subcutaneous ublituximab and received FDA IND clearance to study azer-cel (allogeneic CD19 CAR-T) in patients with progressive MS Conference call to be held today, August 6, 2024, at 8:30 AM ET NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the second quarter of 2024, along with recent company developments and provided an update on...

GlobalFoundries Reports Second Quarter 2024 Financial Results

Written by Customer Service on August 6, 2024. Posted in Public Companies.

MALTA, N.Y., Aug. 06, 2024 (GLOBE NEWSWIRE) — GlobalFoundries Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the second quarter ended June 30, 2024. Key Second Quarter Financial HighlightsRevenue of $1.632 billion Gross margin of 24.2% and Non-IFRS gross margin(1) of 25.2% Operating margin of 9.5% and Non-IFRS operating margin(1) of 13.0% Net income of $155 million and Non-IFRS net income(1) of $211 million Non-IFRS Adjusted EBITDA(1) of $610 million Cash, cash equivalents and marketable securities of $4.1 billion Year to date net cash provided by operating activities of $890 million and Non-IFRS adjusted free cash flow of $563 million“In the second quarter, GF delivered financial results that exceeded the mid-point of the guidance ranges we provided in our May earnings release, thanks to the...

YieldMax™ ETFs Announces Monthly Distributions on MSTY (95.14%), TSLY (83.44%), CONY (75.83%), NVDY (64.52%), CRSH (61.10%) and Others

Written by Customer Service on August 6, 2024. Posted in Dividend Reports And Estimates.

CHICAGO and MILWAUKEE and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) — YieldMax™ today announced monthly distributions for the YieldMax™ ETFs listed in the table below. Note: DIPS, FIAT and CRSH are hereinafter referred to as the “Short ETFs”.ETF Ticker1 ETF Name Reference Asset Distribution per Share Distribution Rate2,4 30-Day SEC Yield3 Ex-Date & Record Date Payment DateTSLY YieldMax™ TSLA Option Income Strategy ETF TSLA $0.9661 83.44% 4.26% 8/7/2024 8/8/2024OARK YieldMax™ Innovation Option Income Strategy ETF ARKK $0.2634 33.00% 4.05% 8/7/2024 8/8/2024APLY YieldMax™ AAPL Option Income Strategy ETF AAPL $0.3498 24.26% 3.81% 8/7/2024 8/8/2024NVDY YieldMax™ NVDA Option Income Strategy ETF NVDA $1.2512 64.52% 4.34% 8/7/2024 8/8/2024AMZY YieldMax™ AMZN Option...

ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance

Written by Customer Service on August 6, 2024. Posted in Earnings Releases And Operating Results.

Generated record quarterly net revenues of $138.0 million, representing year-over-year growth of 18.4%, and record Rare Disease net revenues of $49.2 million, an increase of 102.4% year-over-year Delivered adjusted non-GAAP EBITDA of $33.2 million, and adjusted non-GAAP diluted earnings per share of $1.02 Net loss available to common shareholders of $(2.7) million and diluted GAAP loss per share of $(0.14) On track to close acquisition of Alimera Sciences, Inc. in the third quarter of 2024, adding two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolio Increased 2024 guidance with expected net revenues of $540 million to $560 million, adjusted non-GAAP EBITDA of $140 million to $150 million and adjusted non-GAAP earnings per share of $4.38 to $4.82 Guidance includes Purified Cortrophin®...

OLAPLEX Reports Second Quarter 2024 Results

Written by Customer Service on August 6, 2024. Posted in Earnings Releases And Operating Results.

Reiterates Fiscal Year 2024 Guidance NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) — Olaplex Holdings, Inc. (NASDAQ: OLPX) (“OLAPLEX” or the “Company”) today announced financial results for the second quarter and six months ended June 30, 2024. Amanda Baldwin, OLAPLEX’s Chief Executive Officer, commented: “Our second quarter performance was in line with our expectations and demonstrated continued stabilization in the business. I am encouraged by the progress we are making on our transformation journey as we delivered on our goals for the first half of the year and are now shifting our focus to the back half of 2024 and beyond. I am confident in the direction we are taking the brand and remain incredibly excited about the long-term growth potential for OLAPLEX.” For the second quarter of 2024 compared...

Ambarella Announces Second Quarter Fiscal Year 2025 Earnings Conference Call to be Held August 27, 2024

Written by Customer Service on August 6, 2024. Posted in Public Companies.

SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) — Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced it will hold its second quarter fiscal year 2025 earnings conference call on Tuesday, August 27, 2024 at 1:30 p.m. (Pacific Time). The company will issue its earnings release after the market closes that same day. Those interested in asking a question on the call are required to register online in advance. Once registered, the dial-in numbers will be provided with a personal identification number (PIN). When dialing in for the live call, the PIN number must be provided to access the call. The live webcast of the conference call, and a webcast replay, will be available at: http://investor.ambarella.com/events.cfm About Ambarella Ambarella’s products are used in a wide variety of human vision and...

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Written by Customer Service on August 6, 2024. Posted in Public Companies.

Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening additional clinical sites in other countries ASHBURN, Va., Aug. 06, 2024 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”) a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced the planned initiation of an investigator-led clinical study in New Zealand to evaluate the safety and efficacy of QRX003 in a pediatric patient with Peeling Skin Syndrome (PSS). QRX003 is Quoin’s most advanced pipeline product and is currently being evaluated in two late stage clinical trials in the United States as a potential...

Closure of Offer for Subscription

Written by Customer Service on August 6, 2024. Posted in Public Companies.

Seneca Growth Capital VCT Plc Closure of Offer for Subscription 6 August 2024 SENECA GROWTH CAPITAL VCT PLC The Directors of Seneca Growth Capital VCT Plc announce that the Offer that opened on 24 August 2023 for subscription for B shares to raise, in aggregate, up to £10 million with an over-allotment facility of up to a further £10 million (before issue costs) (the “Offer”) will close for new applications at noon on Thursday, 8 August 2024. The revised deadlines for the receipt of application forms for investment and the closing date for the current Offer are as follows:application forms with cleared funds must arrive by no later than noon on Thursday, 8 August 2024, for final allotment under the current Offer on Friday 9 August 2024 after which the Offer will close.An application form for the Offer is available on...

The results of the voluntary takeover offer made by AS Infortar in respect of the shares of AS Tallink Grupp

Written by Customer Service on August 6, 2024. Posted in Public Companies.

On 2 July 2024, a shareholder of AS Tallink Grupp, AS Infortar (registry code: 10139414, “Offeror”), notified of making a voluntary takeover offer to acquire all shares of AS Tallink Grupp not in the ownership of the Offeror. Today, on 6 August 2024, the Offeror published the results of the voluntary takeover offer. The Chairman of the Management Board of AS Tallink Grupp Paavo Nõgene: „We are pleased that our majority shareholder Infortar has increased its holding in Tallink. This demonstrates their confidence in our company and team, as well as continued faith in our future and readiness to further develop Tallink.” Below we publish the Offeror’s notice regarding the results of the voluntary takeover offer as it was originally made by the Offeror.The results of the voluntary takeover offer made in respect of the shares of AS...

Day: August 6, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice